AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39173098
Drug: placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus chemotherapy
Trial: 33079463
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g glycidyl ester-rich palm fat
Trial: 33079463
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g 2/3-MCPD ester-rich hazelnut oil
Trial: 36158840
Drug: Alprostadil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil (40 μg, three times per day)
Trial: 36158840
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (5 mg, three times per day)
Trial: 32971524
Drug: Silymarin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140 mg, 3 times a day)
Trial: 34506937
Drug: Capsules containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing 300 mg of standardized extract from B. forficata leaves (2% total flavonoid content)
Trial: 35420397
Drug: SARAsp‐Mix (biosimilar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARAsp‐Mix (biosimilar insulin aspart premix SAR341402 Mix 70/30)
Trial: 35420397
Drug: NN‐Mix (originator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN‐Mix (originator insulin aspart mix 70/30 - NovoMix® 30)
Trial: 36401921
Drug: Parenteral vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral vitamin C (100 mg/kg/d for 4 days)
Trial: 34493575
Drug: Infarct progression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infarct progression rate (mL/h)
Trial: 35883016
Drug: Script to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Script to explain the delayed antibiotic trial group
Trial: 36243576
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid 1 g
Trial: 36243576
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid 0.5 g
Trial: 32660667
Drug: Oral quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinine and intragastric placebo (OQGP)
Trial: 32660667
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo and intragastric quinine (OPGQ)
Trial: 32660667
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo and intragastric placebo (OPGP)
Trial: 32660667
Drug: Oral quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinine and intragastric quinine (OQGQ)
Trial: 39379462
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICI)
Trial: 35357449
Drug: Taxane chemotherapy
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane chemotherapy
Trial: 32650126
Drug: Management/adjuvant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management/adjuvant therapy recommendations
Trial: 36065582
Drug: Outpatient psychiatric
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient psychiatric treatment including intensive case management
Trial: 33428907
Drug: E4 15
RxNorm normalized name: Ethinylestradiol 15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E4 15 mg/DRSP 3 mg (E4/DRSP)
Trial: 33428907
Drug: Ethinylestradiol (EE)
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinylestradiol (EE) 30 µg/levonorgestrel (LNG)
Trial: 33428907
Drug: EE 20
RxNorm normalized name: AcidFree 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 20 µg/DRSP 3 mg
Trial: 33428907
Drug: EE 30
RxNorm normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 30 µg/LNG 150 µg
Trial: 36223288
Drug: Baerveldt 101-350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baerveldt 101-350 Glaucoma Implant (BGI)
Trial: 36339126
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (A)
Trial: 35107354
Drug: sMCL augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sMCL augmentation repair
Trial: 34187228
Drug: Lidocaine as
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine as a sodium channel blocker
Trial: 32647051
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Training (HIIT) - 4 × 4‐min HIIT (85‐95% peak heart rate) performed thrice weekly for 12 weeks
Trial: 33755218
Drug: Chlorhexidine oral
RxNorm normalized name: chlorhexidine Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine oral rinse and oropharyngeal spray
Trial: 34848169
Drug: Aflibercept 2
RxNorm normalized name: ziv-aflibercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2 mg every 4 weeks (2q4)
Trial: 34848169
Drug: Aflibercept 2
RxNorm normalized name: ziv-aflibercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2 mg every 8 weeks after 3 monthly doses (2q8)
Trial: 32737183
Drug: Muscimol infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Muscimol infusion into the periaqueductal gray (PAG)
Trial: 32737183
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion into the PAG
Trial: 34928310
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (intravenous, inhalational, or combined anesthetic agents; n=474)
Trial: 34262260
Drug: TPN171H (5-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN171H (5-30 mg dose range)
Trial: 34262260
Drug: TPN171H (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN171H (multiple dosing)
Trial: 35997620
Drug: mDOT (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mDOT (modified directly observed therapy)
Trial: 35997620
Drug: Overall HCV
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall HCV treatment
Trial: 33564828
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplementation (20 g/d soy protein isolate, providing 41 mg/d total isoflavones and 23 mg/d genistein)
Trial: 33196579
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy (not explicitly mentioned but implied as control)
Trial: 32778008
Drug: Iron-fortified formula
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified formula (12.7 mg/L)
Trial: 34174564
Drug: Dietary tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary tryptophan levels of 1.00, 2.00, 3.00, 4.00, 5.00, and 6.00 g/kg
Trial: 33676589
Drug: Tocilizumab 6
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 6 mg/kg plus standard care
Trial: 33564844
Drug: Heavy resistance
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy resistance training 3 times weekly with whey protein supplementation (HRTW)
Trial: 33395498
Drug: Twice-weekly Structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly Structured Interdisciplinary Bedside Rounds (SIBR)
Trial: 32620866
Drug: Spa-rehab therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa-rehab therapy
Trial: 32620866
Drug: Standard spa
RxNorm normalized name: A-Spas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard spa therapy
Trial: 36114653
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester (27 g per dose, thrice daily for 3 days)
Trial: 35330843
Drug: Abacus mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacus mental calculation training (AMC); specific dosage and duration not mentioned.
Trial: 36513442
Drug: Moderate daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate daily consumption of cachaça (28 g ethanol/day for men, 14 g for women)
Trial: 36513442
Drug: Moderate daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate daily consumption of red wine (28 g ethanol/day for men, 14 g for women)
Trial: 32224129
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control strategy (increased therapy based on fecal calprotectin, serum C-reactive protein, and symptoms)
Trial: 32224129
Drug: Deep remission
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep remission (CD endoscopic index of severity scores below 4, no deep ulcerations or steroid treatment for 8 or more weeks)
Trial: 33969511
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation model led by a hospital clinical pharmacist
Trial: 34964311
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day plus rifaximin 1,200 mg/day for 3 months
Trial: 34146594
Drug: 4-g Alkyrol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-g Alkyrol® (purified shark liver oil) per day for 3 weeks
Trial: 35940529
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 50 mg/kg daily from 9 days before HSCT to 30 days after HSCT
Trial: 33832645
Drug: Meclon Idra
RxNorm normalized name: Idralazina
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclon Idra vaginal gel
Trial: 35190840
Drug: Hemoglobin concentration
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin concentration ≤ 10.9 g/dL
Trial: 32734919
Drug: Goal Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal Management Training (GMT); 9 sessions, 2 hours each, once weekly (n = 35)
Trial: 32734919
Drug: Computerized Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized Cognitive Training (CCT); 9 sessions, 1 hour each, twice weekly (n = 28)
Trial: 32745244
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion adjusted by a standard algorithm
Trial: 32014046
Drug: Financial incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial incentives in addition to interactive management of mobile devices, conditional on achieving antihypertensive goals.
Trial: 34851445
Drug: Oral triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triiodothyronine (T3)
Trial: 32875813
Drug: Treatment 1
RxNorm normalized name: CVS Acne Treatment 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 1 (T1): Vaccinated against ND+IB on days 7 and 14;
Trial: 32875813
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2 (T2): Vaccinated against ND+IB on days 3 and 7, and IBD on day 14;
Trial: 32875813
Drug: Treatment 3
RxNorm normalized name: Canesten Clotrimazole Thrush Treatment 3 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 3 (T3): Vaccinated against ND+IB on days 7 and 21, and IBD on day 14;
Trial: 34767967
Drug: rTMS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS therapy with individualized MRI guidance
Trial: 34767967
Drug: Scalp-targeting rules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp-targeting rules (e.g., Beam F3)
Trial: 36471691
Drug: SBRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBRT + K + M (Stereotactic Body Radiation Therapy with Pembrolizumab and Trametinib)
Trial: 36471691
Drug: SBRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBRT + G (Stereotactic Body Radiation Therapy with Gemcitabine)
Trial: 36471691
Drug: SBRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBRT + G
Trial: 32067259
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high baseline TMTV and poor iPET response
Trial: 35296289
Drug: Information related
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information related to AstraZeneca's vaccine safety, misinformation, individual health risks, and public health risks.
Trial: 33637064
Drug: Sodium hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronic acid (HA) treatment
Trial: 32073676
Drug: Beta-blockers withdrawal
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers withdrawal
Trial: 32073676
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (beta-blockers continued)
Trial: 36159218
Drug: PIPAC in
RxNorm normalized name: ZINC OXIDE 6.25 g in 50 g CUTANEOUS CREAM [PIPA SKIN CARE SUN-SATIONAL Mineral Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIPAC in combination with systemic chemotherapy
Trial: 35136595
Drug: Universal home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Universal home visits to pregnant women and their spouses (two-monthly visits)
Trial: 34840289
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral intervention for anger management (two individual monthly sessions by a psychologist)
Trial: 34038558
Drug: Test meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test meal with 300 mL of tea
Trial: 33580553
Drug: Comprehensive face‐to‐face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive face‐to‐face medicine management consultation with an integrated practice pharmacist within seven days of discharge, followed by a consultation with their general practitioner and further pharmacist consultations as needed.
Trial: 32746928
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of salient price increases and discounts
Trial: 33686630
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl 100 µg
Trial: 33686630
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl 200 µg
Trial: 33686630
Drug: Oxycodone (control)
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone (control)
Trial: 33686630
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (both doses)
Trial: 35879705
Drug: 0.075% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% ropivacaine and 0.5 µg/mL sufentanil
Trial: 35879705
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine and 0.5 µg/mL sufentanil
Trial: 36067452
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy with cetuximab (anti-EGFR-chemotherapy)
Trial: 36067452
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy with bevacizumab (anti-VEGF-chemotherapy)
Trial: 36067452
Drug: Later-line anti-EGFR-antibody
RxNorm normalized name: Anti-egfr/anti-c-met bispecific antibody emb-01
DrugBank: EMB-01 (DB16091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later-line anti-EGFR-antibody therapy
Trial: 34407860
Drug: Focal therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal therapy (specifics not provided)
Trial: 33285195
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) with a median dose of 33.3 Gy (range: 27 to 54 Gy) in 5 fractions
Trial: 33285195
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) followed by sorafenib
Trial: 32272505
Drug: Trials that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trials that randomized or mandated hormone therapy
Trial: 32272505
Drug: Trials that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trials that did not randomize or mandate endocrine therapy
Trial: 34351356
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) with S-1
Trial: 33032234
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy with systemic antibiotics (PT1 group)
Trial: 33032234
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy without antibiotics (PT2 group)
Trial: 33032234
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) with no periodontal therapy
Trial: 33032234
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (PT1 and PT2)
Trial: 32811843
Drug: ADV7103 (alkalising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV7103 (alkalising agent) at doses of 1.44 meq/kg twice a day
Trial: 36153625
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 4 mg/kg/h continuous infusion)
Trial: 36153625
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (same volumes as lidocaine)
Trial: 33599356
Drug: E6011 (anti-fractalkine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 (anti-fractalkine antibody) 2, 5, 10, and 15 mg/kg intravenously every 2 weeks during the 12-week multiple ascending dose phase.
Trial: 33289953
Drug: AGS‐16C3F 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGS‐16C3F 1.8 mg/kg every 3 weeks
Trial: 33289953
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg twice daily (starting dose)
Trial: 33922334
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group with visual and oral instructor prompts to stand
Trial: 35258786
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone
Trial: 32954688
Drug: Sina curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sina curcumin capsules 80 mg
Trial: 35464292
Drug: Intravenous dasiglucagon
RxNorm normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dasiglucagon (doses ranged from 0.03 mg to 1.5 mg)
Trial: 35464292
Drug: Subcutaneous dasiglucagon
RxNorm normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous dasiglucagon (0.6 mg)
Trial: 34266452
Drug: Aspirin, Atorvastatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, Atorvastatin, Nicorandil (Aspirin 325 mg starting dose, 75 mg once daily; Atorvastatin 40 mg starting dose, 40 mg once daily; Nicorandil 10 mg starting dose, 5 mg twice daily) plus conventional therapy
Trial: 32052264
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg BID
Trial: 36397132
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) with ivermectin (IVM) and dihydroartemisinin-piperaquine, administered in three monthly rounds at the beginning of the malaria transmission season.
Trial: 36397132
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) with ivermectin (IVM) and dihydroartemisinin-piperaquine.
Trial: 35605609
Drug: Pramipexole (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (dose titrated from 0.25 mg/d to 1.0 mg/d)